Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial
Mona Ahmadi(Imam Khomeini Hospital), Abbas Tafakhori(Tehran University of Medical Sciences), Shahriar Nafissi(Shariati Hospital), Mahmoud Reza Jaafari(Mashhad University of Medical Sciences), Sara Faghihi‐Kashani(San Francisco VA Medical Center), Mohammad Hossein Harirchian(Iran University of Medical Sciences), Mostafa Hosseini(Tehran University of Medical Sciences), Abdoreza Ghoreishi(Zanjan University of Medical Sciences), Elmira Agah(University of California, Davis), Seyed Jalal Eshagh Hosseini(Imam Khomeini Hospital), Payam Sarraf(Tehran University of Medical Sciences), Vajiheh Aghamollaii(Roozbeh Hospital)
Cited by 142
Related Papers
Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region
|Journal of Controlled Release|2015|83
A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis
|Seminars in Arthritis and Rheumatism|2017|71
An inverse association between serum vitamin D levels with the presence and severity of impaired nerve conduction velocity and large fiber peripheral neuropathy in diabetic subjects
|Neurological Sciences|2015|58
Bi-allelic HPDL Variants Cause a Neurodegenerative Disease Ranging from Neonatal Encephalopathy to Adolescent-Onset Spastic Paraplegia
|The American Journal of Human Genetics|2020|54
Bi-allelic variants in RNF170 are associated with hereditary spastic paraplegia
|Nature Communications|2019|53